Lung cancer is an umbrella term for a range of subtypes, with different subtypes having different biological behaviors. The disease is the leading cancer mortality factor for Americans. Each year, 220,000 adults are diagnosed with lung cancer, and only 16% of them survive for five years. This is despite the fact that tobacco is the cause of the vast majority of lung cancers. However, more than 80 percent of patients diagnosed in 2013 were non-smokers or had quit smoking at the time of diagnosis. The discovery of key driver genes has shifted the focus of lung cancer treatment to targeted therapies. This year, researchers have found that screening for mutated genes can help individualize treatment and ultimate survival. In addition, results from an early study found that dabrafenib has therapeutic activity in BRAF-positive non-small cell lung cancer patients. Based on the results of gene mutation testing, drug selection can help patients’ survival According to a large clinical trial conducted by NIH, about 2/3 of patients with the most common type of lung cancer, lung adenocarcinoma, may have at least one gene mutation. The French lung cancer driver gene screening program has been successfully conducted in France. The results of the Phase 2 clinical trial showed a tumor shrinkage rate of approximately 54%, a significant improvement over the traditional single drug of approximately 15%, with the longest duration of response lasting approximately 11 months. The results of the phase 3 clinical trial are noteworthy. FDA approved albumin-bound paclitaxel, erlotinib, and afatinib for the treatment of metastatic non-small cell lung cancer. FDA approves Abraxane as a first-line agent for advanced NSCLCFDA approves Erlotinib for first-line treatment of metastatic NSCLCFDA approves Afatinib for advanced NSCLC with EGFR gene mutation